Amneal Pharmaceuticals, Class Stock Today
| AMRX Stock | USD 8.89 0.23 2.66% |
PerformanceOK
| Odds Of DistressLow
|
Amneal Pharmaceuticals, is trading at 8.89 as of the 25th of March 2025; that is 2.66 percent up since the beginning of the trading day. The stock's open price was 8.66. Amneal Pharmaceuticals, has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Note, on June 15, 2019, Representative Josh Gottheimer of US Congress acquired under $15k worth of Amneal Pharmaceuticals,'s common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of January 2009 | Category Healthcare | Classification Health Care |
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. The company has 309.97 M outstanding shares of which 2.76 M shares are presently shorted by private and institutional investors with about 1.96 trading days to cover. More on Amneal Pharmaceuticals, Class
Moving together with Amneal Stock
Moving against Amneal Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Amneal Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Chintu Patel | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAmneal Pharmaceuticals, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amneal Pharmaceuticals,'s financial leverage. It provides some insight into what part of Amneal Pharmaceuticals,'s total assets is financed by creditors.
| |||||
Amneal Pharmaceuticals, Class (AMRX) is traded on New York Stock Exchange in USA and employs 8,300 people. Amneal Pharmaceuticals, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.11 B. Amneal Pharmaceuticals, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 309.97 M outstanding shares of which 2.76 M shares are presently shorted by private and institutional investors with about 1.96 trading days to cover.
Amneal Pharmaceuticals, Class currently holds about 87.33 M in cash with 295.1 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58.
Check Amneal Pharmaceuticals, Probability Of Bankruptcy
Ownership AllocationAmneal Pharmaceuticals, holds a total of 309.97 Million outstanding shares. Amneal Pharmaceuticals, Class retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. On June 15, 2019, Representative Josh Gottheimer of US Congress acquired under $15k worth of Amneal Pharmaceuticals,'s common stock.
Check Amneal Ownership Details
Amneal Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nuveen Asset Management, Llc | 2024-12-31 | 2.7 M | |
| Amvescap Plc. | 2024-12-31 | 1.9 M | |
| Northern Trust Corp | 2024-12-31 | 1.8 M | |
| Hennessy Advisors, Inc. | 2024-12-31 | 1.7 M | |
| Ubs Group Ag | 2024-12-31 | 1.7 M | |
| Arrowstreet Capital Limited Partnership | 2024-12-31 | 1.5 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.5 M | |
| Ameriprise Financial Inc | 2024-12-31 | 1.5 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.5 M | |
| Vanguard Group Inc | 2024-12-31 | 14.8 M | |
| Blackrock Inc | 2024-12-31 | 12.6 M |
Amneal Pharmaceuticals, Historical Income Statement
Amneal Stock Against Markets
Already Invested in Amneal Pharmaceuticals, Class?
The danger of trading Amneal Pharmaceuticals, Class is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amneal Pharmaceuticals, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amneal Pharmaceuticals,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amneal Pharmaceuticals, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.